摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

戊氟甲噻嗪 | 1766-91-2

中文名称
戊氟甲噻嗪
中文别名
3-戊基-6-(三氟甲基)-3,4-二氢-2H-苯并[e][1,2,4]噻二嗪-7-磺酰胺1,1-二氧化物;戊氟噻嗪
英文名称
penflutizide
英文别名
penfluzide;3-Pentyl-7-sulfamoyl-6-trifluormethyl-3,4-dihydro-1,2,4-benzothiadiazin-1,1-dioxid;1,1-dioxo-3-pentyl-6-trifluoromethyl-1,2,3,4-tetrahydro-1λ6-benzo[1,2,4]thiadiazine-7-sulfonic acid amide;1,1-dioxo-3-pentyl-6-(trifluoromethyl)-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
戊氟甲噻嗪化学式
CAS
1766-91-2
化学式
C13H18F3N3O4S2
mdl
——
分子量
401.431
InChiKey
AKHXXQAIVSMYIS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    547.4±60.0 °C(Predicted)
  • 密度:
    1.411±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    25
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    135
  • 氢给体数:
    3
  • 氢受体数:
    10

安全信息

  • 海关编码:
    2935009090

上下游信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2010137738A1
    公开(公告)日:2010-12-02
    The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    本发明提供了一种新颖的杂环化合物。一种由通式(1)表示的杂环化合物,其中,R1和R2分别独立表示氢;苯基较低烷基基团,可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基;或环C3-C8烷基较低烷基基团;或类似物;R3表示较低炔基基团或类似物;R4表示可能具有从1,3,4-噁二唑基团(例如,卤素)或从吡啶基团等组成的取代基的苯基团;所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
  • Aromatic amine derivative and use thereof
    申请人:Taniguchi Takahiko
    公开号:US20090325956A1
    公开(公告)日:2009-12-31
    The present invention provides a novel SCD inhibitor. An SCD inhibitor containing a compound represented by the formula [I] wherein ring A is an optionally substituted aromatic ring, ring B is an optionally substituted ring, ring C is an optionally substituted aromatic ring, R is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and X is a spacer having 1 to 5 atoms in the main chain, or a salt thereof, or a prodrug thereof.
    本发明提供了一种新型SCD抑制剂。一种包含由下式[I]表示的化合物的SCD抑制剂 其中环A是可选择取代的芳香环,环B是可选择取代的环,环C是可选择取代的芳香环,R是氢原子,可选择取代的碳氢基团或可选择取代的杂环基团,X是具有主链中1到5个原子的间隔物,或其盐,或其前药。
  • [EN] FUSED RING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS ET UTILISATION DE CEUX-CI
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2009125873A1
    公开(公告)日:2009-10-15
    The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
    本发明旨在提供一种葡萄糖激酶激活剂,可用作药用剂,如用于预防或治疗糖尿病、肥胖等疾病的药剂。本发明提供一种包含由式(I)表示的化合物的葡萄糖激酶激活剂:其中每个符号在规范中有定义,或其盐或前药。
  • [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2005105802A1
    公开(公告)日:2005-11-10
    The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.
    本发明旨在提供一种具有神经激肽2(NK2)受体拮抗作用的喹啉生物,并涉及一种由式(I)表示的化合物,其中R1是氢原子等;R2是氢原子,可选地具有取代基的碳氢基团等;R3是未取代的(即缺失),氢原子等;R4和R5相同或不同,每个是氢原子,可选地具有取代基的碳氢基团等;R6是(环状基团,可选地具有取代基)-羰基等;R7、R8、R9和R10相同或不同,每个是氢原子,卤素等;或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环;n是1到5的整数;---表示未取代的(即缺失)或单键;---表示单键或双键,或其盐等。
  • [EN] AGENT FOR PREVENTING OR TREATING NEUROPATHY<br/>[FR] AGENT POUR LA PRÉVENTION OU LE TRAITEMENT DE NEUROPATHIE
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2004039365A1
    公开(公告)日:2004-05-13
    The present invention provides an agent for preventing or treating neuropathy having superior action and low toxicity. This agent comprises a compound represented by the formula:wherein ring A is a 5-membered aromatic heterocycle containing 2 or more nitrogen atoms, which may further have substituent(s);B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;X is a divalent acyclic hydrocarbon group;Z is -O-, -S-, -NR2-, -CONR2- or -NR2CO- (R2 is a hydrogen atom or an optionally substituted alkyl group);Y is a bond or a divalent acyclic hydrocarbon group;R1 is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, provided that when the 5-membered aromatic heterocycle represented by ring A is imidazole, then Z should not be -O-, or a salt thereof.
    本发明提供了一种具有优越作用和低毒性的预防或治疗神经病的药剂。该药剂包括一个由以下式表示的化合物:其中环A是含有2个或更多氮原子的5元芳香杂环,可能进一步具有取代基;B是一个可选择取代的碳氢基团或可选择取代的杂环基团;X是二价的无环碳氢基团;Z是-O-,-S-,-NR2-,-CONR2-或-NR2CO-(R2是氢原子或可选择取代的烷基基团);Y是键或二价的无环碳氢基团;R1是可选择取代的环基团,可选择取代的基团或可选择取代的酰基团,但当环A表示的5元芳香杂环是咪唑时,Z不应为-O-,或其盐。
查看更多